Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | Chief Financial Officer | January 04, 2021 | January 06, 2021 |
| Jade Biosciences, Inc.JBIO · Entity 4757 | Chief Financial Officer | February 12, 2026 | February 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 04, 2021 · Filed January 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,000 |
Reported balance
After 2021-01-04 transaction · row 1
1 source rowRow 1 · 2021-01-04 · Grant · Acquired 38,000 · Balance 38,000 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 4, 2022. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 4, 2025. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2031-01-03 | Direct | 230,000 |
Reported balance
After 2021-01-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-04 · Grant · Acquired 230,000 · Balance 230,000 F2: This option vests as to 25% on January 4, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 4, 2022. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 4, 2025.
F2: This option vests as to 25% on January 4, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.
Jade Biosciences, Inc.
Report date February 12, 2026 · Filed February 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,813 |
Reported balance
After 2026-02-12 transaction · row 1
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 37,813 · Balance 37,813 F1: Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.81 · Expires 2036-02-11 | Direct | 226,875 |
Reported balance
After 2026-02-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-12 · Grant · Acquired 226,875 · Balance 226,875 F2: This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theseus Pharmaceuticals, Inc.
Report date February 14, 2024 · Filed February 14, 2024
Section 16 reporting ended · disclosed 2024-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-14 transaction · row 1
1 source rowRow 1 · 2024-02-14 · Other · Disposed 8,150.225 · Balance 0 F1: Includes 2,008 shares acquired under the Issuer's employee stock purchase plan on May 12, 2023. F2: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger. F3: At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $4.05 per Share in cash (the "Cash Amount"), subject to any applicable withholding taxes and without interest, plus (b) one non-transferable contractual contingent value right per Share (each, a "CVR"), which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-14 · Disposition to issuer · Disposed 17,500 · Balance 0 F4: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F5: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.03 | Direct | 0 |
Reported balance
After 2024-02-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-14 · Disposition to issuer · Disposed 332,114 · Balance 0 F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,008 shares acquired under the Issuer's employee stock purchase plan on May 12, 2023.
F2: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger.
F3: At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $4.05 per Share in cash (the "Cash Amount"), subject to any applicable withholding taxes and without interest, plus (b) one non-transferable contractual contingent value right per Share (each, a "CVR"), which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.
F4: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share.
F5: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU.
F6: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2026 Filed Feb 14, 2026 01:00 UTC | Jade Biosciences, Inc. JBIO · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 226,875 | $0.00 Strike: $14.81 | $0.00 |
DisclosureSEC source: 0001193125-26-052056 · ownership.xml · derivative · entry 2 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,875 Underlying: Common Stock · 226,875 shares Expires 2036-02-11 F2 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 12, 2026 Filed Feb 14, 2026 01:00 UTC | Jade Biosciences, Inc. JBIO · Entity 4757 | GrantCommon Stock | 37,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-052056 · ownership.xml · nonDerivative · entry 1 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,813 F1 · shares: Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| July 14, 2025 Filed Jul 14, 2025 23:12 UTC | Jade Biosciences, Inc. JBIO · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 526,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0000950170-25-095668 · ownership.xml · derivative · entry 1 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526,000 Underlying: Common Stock · 526,000 shares Expires 2035-07-14 F1 · derivative.exercise_date: This option represents a right to purchase 526,000 shares of the Issuer's common stock, one quarter of which will vest on July 14, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| February 14, 2024 Filed Feb 14, 2024 16:00 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | Disposition to issuerStock Option (Right to Buy) · Derivative | 332,114 | Not disclosed Strike: $4.03 | Not disclosed |
DisclosureSEC source: 0001104659-24-023551 · tm246087-1_4seq1.xml · derivative · entry 3 Dahms Bradford D. · CIK 0001787307 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 332,114 shares Expires not disclosed F6 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer Stock Option with an exercise price that is less than the Cash Amount was cancelled and converted into the right to receive (i) a cash payment equal to the product of (A) the excess, if any, of the Cash Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time and (ii) one CVR for each Share underlying such Issuer Stock Option. Read SEC document |
| February 14, 2024 Filed Feb 14, 2024 16:00 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | Disposition to issuerRestricted Stock Units · Derivative | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-023551 · tm246087-1_4seq1.xml · derivative · entry 2 Dahms Bradford D. · CIK 0001787307 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires not disclosed F4 · derivative.exercise_price: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F5 · price: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU. Read SEC document |
| February 14, 2024 Filed Feb 14, 2024 16:00 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | OtherCommon Stock | 8,150.225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-023551 · tm246087-1_4seq1.xml · nonDerivative · entry 1 Dahms Bradford D. · CIK 0001787307 · President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 2,008 shares acquired under the Issuer's employee stock purchase plan on May 12, 2023. F2 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger. F3 · price: At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $4.05 per Share in cash (the "Cash Amount"), subject to any applicable withholding taxes and without interest, plus (b) one non-transferable contractual contingent value right per Share (each, a "CVR"), which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 07:00 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | GrantRestricted Stock Units · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-027624 · tm237858-2_4seq1.xml · derivative · entry 1 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the RSUs vesting on March 1, 2024 and 1/16th of the RSUs vesting quarterly thereafter, subject to the Reporting Person's continuous service with the issuer. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the RSUs vesting on March 1, 2024 and 1/16th of the RSUs vesting quarterly thereafter, subject to the Reporting Person's continuous service with the issuer. The RSUs have no expiration date. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 07:01 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $11.42 | $0.00 |
DisclosureSEC source: 0001104659-23-023506 · tm237110-2_4seq1.xml · derivative · entry 1 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2033-02-17 F1 · derivative.exercise_date: The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on February 17, 2024 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer. Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 16:35 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | PurchaseCommon Stock | 1,502.189 | $6.66 | $10,000.07 |
DisclosureSEC source: 0001104659-22-123686 · tm2231776-1_4seq1.xml · nonDerivative · entry 1 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,142.225 F1 · price: The price reported is a weighted average price of shares purchased. These shares were purchased in multiple transaction at prices ranging from $6.56 to $6.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 1,162 shares and 1,508 shares previously purchased under the Issuer's 2021 Employee Stock Purchase Plan on May 13, 2022 and November 14, 2022, respectively. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 20:00 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $11.21 | $0.00 |
DisclosureSEC source: 0000899243-22-007498 · doc4.xml · derivative · entry 1 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 25% of the options vesting on February 18, 2023 and 1/48th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 18:21 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | PurchaseCommon Stock | 1,970.036 | $10.15 | $20,000.00 |
DisclosureSEC source: 0000899243-21-049427 · doc4.xml · nonDerivative · entry 1 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,970.036 F1 · price: The price reported is a weighted average price of shares purchased. These shares were purchased in multiple transaction at prices ranging from $10.09 to $10.28, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:49 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001453687-21-000015 · wf-form4_160996976014499.xml · derivative · entry 2 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2031-01-03 F2 · derivative.exercise_date: This option vests as to 25% on January 4, 2022. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:49 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-21-000015 · wf-form4_160996976014499.xml · nonDerivative · entry 1 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 4, 2022. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 4, 2025. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 20:11 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001104659-20-081211 · a4.xml · derivative · entry 1 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: This option will vest as to 25% on July 1, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:07 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001453687-20-000010 · wf-form4_157835920999505.xml · derivative · entry 1 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 21:29 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001453687-19-000133 · wf-form4_156771897844321.xml · derivative · entry 1 Dahms Bradford D. · CIK 0001787307 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-09-02 F1 · derivative.exercise_date: This option vests as to 25% on September 3, 2020, and the remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.